Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Slides:

Advertisements

Similar presentations

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States David B. Seifer, M.D., Valerie.

Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Evaluation of the relationship between follicular fluid oxidative stress, ovarian hormones, and response to gonadotropin stimulation Malathy Appasamy,

Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis Konstantinos A. Toulis, M.D.,

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Age at menarche: a predictor of diminished ovarian function?

Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

MRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome.

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase Michael von Wolff, M.D., Christian J. Thaler,

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis

Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials Ana Cobo, Ph.D., César Diaz, M.D.

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome Sigrun B. Kjøtrød, M.D., Arne.

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D

Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.

Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles Reshef Tal, David B. Seifer, Moisey Khanimov, Eliana.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.

Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle James R. Stelling, M.D., Emily.

A comparison of blood spot vs

Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with.

The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging Eriko Y. Fujii, M.D., Ph.D.,

Oocyte cryopreservation

Evolutionary determinants of polycystic ovary syndrome: part 1

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Angela R. Baerwald, Ph. D. , Olufemi A. Olatunbosun, M. D. , Roger A

Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea Hang Wun Raymond Li,

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Robert F. Casper, M.D. Fertility and Sterility

Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial.

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Ovulation induction in women with polycystic ovary syndrome

Introduction Fertility and Sterility

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Increased secretion of amylin in women with polycystic ovary syndrome

Follicular-fluid neurotrophin levels in women undergoing assisted reproductive technology for different etiologies of infertility Erkan Buyuk, M.D.,

Endocrine gland–derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome.

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Inappropriate gonadotropin secretion in polycystic ovary syndrome

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Soluble HLA-G in the peritoneal fluid of women with endometriosis

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles David.

Altered circulating levels of matrix metalloproteinases 2 and 9 and their inhibitors and effect of progesterone supplementation in women with endometriosis.

Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test Dimitrios Panidis, M.D., Ph.D., Dimitrios.

Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation Janet F. McLaren, M.D., Richard O. Burney,

Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels

Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low-grade inflammation in polycystic ovary syndrome and obesity?

Presentation transcript:

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef Tal, M.D., Ph.D., David B. Seifer, M.D., Aya Shohat-Tal, Ph.D., Richard V. Grazi, M.D., Henry E. Malter, Ph.D. Fertility and Sterility Volume 100, Issue 2, Pages 538-543 (August 2013) DOI: 10.1016/j.fertnstert.2013.04.022 Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 1 TGF-β1 concentration in (A) serum (ng/mL) and (B) follicular fluid (pg/mL) of women with PCOS and non-PCOS women undergoing COS. Data are presented as mean ± SD. ∗P=.02 and ∗∗P<.01 for PCOS versus non-PCOS women. Fertility and Sterility 2013 100, 538-543DOI: (10.1016/j.fertnstert.2013.04.022) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Soluble ENG concentration (ng/mL) in serum (A) and follicular fluid (B) of PCOS and non-PCOS women undergoing COS. Data are presented as mean ± SD. ∗P=.04 and ∗∗P<.01 for PCOS vs. non-PCOS women; +P=.02 for day of oocyte retrieval vs. day 3 and day of hCG in non-PCOS group. Fertility and Sterility 2013 100, 538-543DOI: (10.1016/j.fertnstert.2013.04.022) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions